Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
0.950
+0.033 (3.64%)
At close: Nov 22, 2024, 4:00 PM
0.998
+0.048 (5.00%)
After-hours: Nov 22, 2024, 7:22 PM EST
Lyell Immunopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0.06 | 0.13 | 84.68 | 10.65 | 7.76 | 0.66 |
| Revenue Growth (YoY) | -99.87% | -99.85% | 695.15% | 37.31% | 1080.52% | - |
| Gross Profit | 0.06 | 0.13 | 84.68 | 10.65 | 7.76 | 0.66 |
| Selling, General & Admin | 50.69 | 66.98 | 117.31 | 89.06 | 46.88 | 39.15 |
| Research & Development | 169.93 | 182.95 | 159.19 | 138.69 | 182.24 | 63.6 |
| Other Operating Expenses | -4.29 | -4.3 | -4.86 | -3.53 | -1.65 | - |
| Operating Expenses | 216.33 | 245.63 | 271.64 | 224.22 | 227.48 | 102.75 |
| Operating Income | -216.26 | -245.5 | -186.96 | -213.57 | -219.72 | -102.09 |
| Interest & Investment Income | 26.23 | 23.45 | 7.05 | 1.17 | 5.94 | 8.12 |
| Other Non Operating Income (Expenses) | -0.15 | 1.85 | 2.95 | 0.1 | 1.53 | -35.41 |
| EBT Excluding Unusual Items | -190.18 | -220.2 | -176.95 | -212.31 | -212.26 | -129.38 |
| Gain (Loss) on Sale of Investments | -12.95 | -12.92 | -6.07 | -36.7 | - | - |
| Gain (Loss) on Sale of Assets | -0.85 | -1.51 | -0.1 | -1.21 | 4.88 | - |
| Other Unusual Items | - | - | - | - | 2.9 | - |
| Pretax Income | -203.99 | -234.63 | -183.12 | -250.22 | -204.47 | -129.38 |
| Net Income | -203.99 | -234.63 | -183.12 | -250.22 | -204.47 | -129.38 |
| Preferred Dividends & Other Adjustments | - | - | - | - | 3.58 | 1.14 |
| Net Income to Common | -203.99 | -234.63 | -183.12 | -250.22 | -208.05 | -130.52 |
| Shares Outstanding (Basic) | 255 | 251 | 247 | 136 | 13 | 5 |
| Shares Outstanding (Diluted) | 255 | 251 | 247 | 136 | 13 | 5 |
| Shares Change (YoY) | 1.82% | 1.58% | 81.79% | 925.18% | 144.21% | - |
| EPS (Basic) | -0.80 | -0.93 | -0.74 | -1.84 | -15.69 | -24.04 |
| EPS (Diluted) | -0.80 | -0.93 | -0.74 | -1.84 | -15.69 | -24.04 |
| Free Cash Flow | -156.23 | -166.38 | -193.83 | -191.75 | -212.36 | 23.43 |
| Free Cash Flow Per Share | -0.61 | -0.66 | -0.78 | -1.41 | -16.02 | 4.32 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -343273.02% | -188845.38% | -220.77% | -2005.31% | -2832.92% | -15538.66% |
| Profit Margin | -323792.06% | -180486.15% | -216.24% | -2349.47% | -2682.49% | -19866.21% |
| Free Cash Flow Margin | -247987.30% | -127984.62% | -228.89% | -1800.50% | -2737.94% | 3565.75% |
| EBITDA | -196.6 | -225.25 | -168.94 | -199.94 | -215.43 | -100.83 |
| EBITDA Margin | - | - | -199.49% | - | - | - |
| D&A For EBITDA | 19.66 | 20.25 | 18.02 | 13.62 | 4.29 | 1.26 |
| EBIT | -216.26 | -245.5 | -186.96 | -213.57 | -219.72 | -102.09 |
| EBIT Margin | - | - | -220.77% | - | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.